Tag: thyroid cancer
Phase 3 LIBRETTO-531 trial : Lilly’s Retevmo meets primary endpoint of PFS
Eli Lilly and Company (NYSE: LLY) unveiled exceptional results from their LIBRETTO-531 study of Retevmo (selpercatinib), setting a new standard in the treatment of advanced ... Read More
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 ... Read More
Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration
Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's Retevmo (selpercatinib) capsules for the treatment of three ... Read More
Lilly bags Retevmo FDA approval for RET-driven lung and thyroid cancers
Retevmo FDA approval : Eli Lilly and Company (Lilly) has secured approval from the US Food and Drug Administration (FDA) for Retevmo (selpercatinib, 40mg and ... Read More
COSMIC-311 clinical trial : Exelixis enrolls patients to study cabozantinib in phase 3 thyroid cancer trial
COSMIC-311 clinical trial : US biotech company Exelixis has enrolled the first 100 patients in a phase 3 trial called COSMIC-311 for evaluating cabozantinib (CABOMETYX) ... Read More